English丨中文
核心技术

我们的核心优势之一,是我们致力于在多靶点siRNA治疗领域巩固和扩大我们的知识产权(IP)组合。目前我们拥有强大的知识产权组合,具有以下特点:


1. Composition Matters: 25 mer blunt-ends siRNA API(s) and polypeptide excipient(s)


2. Method of Use: nanoparticle packaged siRNA duplexes for local or systemic administration


3. Utilities: unmet clinical needs with big market potential, such as hypertrophic scar prevention and treatment, influenza prophylaxis and therapeutics, cancer treatment.


4. In-house developed: 10 PCTs, 2 US patent applications. 5 European and China national phase applications. Three issued US patents protecting STP705, STP702 and STP503.


5. Licensing: 2 issued patents licensed from Prof. James Mixson and University of Hong Kong, China.